Clinical Research
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 28, 2005; 11(44): 6988-6994
Published online Nov 28, 2005. doi: 10.3748/wjg.v11.i44.6988
Figure 1
Figure 1 Anti-Saccharomyces cerevisiae (A) IgG and (B) IgA antibody titers in ASCA-positive patients with Crohn’s disease expressed as a logarithmically (ln) scaled dilution unit of a highly positive control over a time-period of up to 3 years.
Figure 2
Figure 2 Histogram of change in ASCA IgA and IgG titers (∆IgG/A) in patients with Crohn’s disease (CD), ulcerative colitis (UC) and irritable bowel syndrome (IBS). CD patients demonstrate higher variability as compared to UC and IBS.
Figure 3
Figure 3 OD at 450 nm representing relative levels of polyclonal anti-Saccharomyces cerevisiae antibody (ASCA) (A) in control Balb/c mice (empty columns) or mice with DSS-induced experimental colitis (shaded columns). Basal ASCA titers were determined at the start of the experiment. During the experiment, mice received water containing 100 μg/mL or 500 μg/mL yeast solution ad libitum. (B) Balb/c mice were immunized with water or 50μg yeast mannan or ovalbumin mixed 1:1 (v:v) in GERBU adjuvant. After 2 wk, mice received a booster injection and ASCA or anti ovalbumin antibodies were determined 7 d later. aP<0.05.